Tenecteplase.txt

CLINICAL USE

Thrombolytic:Acute myocardial infarction

DOSE IN NORMAL RENAL FUNCTION

30–50 mg depending on patient weight (500–600 micrograms/kg)

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :70 000

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data

%Excreted unchanged in urine &nbsp &nbsp : Minimal

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :6.1–9.1 litres1 (weight and dose related)

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :90–130 minutes/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsDrugs that affect coagulation or platelet function: increased risk of bleeding

ADMINISTRATION

Reconstition

Water for injection

Route

Rate of Administration

Over 10 seconds

Comments

Incompatible with dextrose

OTHER INFORMATION

It has an initial half-life of 20–24 minutes Cleared mainly by hepatic metabolism Re-administration is not recommended due to lack of experience

Tags: post-by-auto-php